Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial

Horn, Deborah B; Ryan, Donna H; Kis, Sanja Giljanovic; Alves, Breno; Mu, Yiming; Kim, Sin Gon; Aberle, Jens; Bain, Steve; Allen, Sheryl; Sarker, Elizabeth; Wu, Qiwei; Stefanski, Adam; Jouravskaya, Irina

doi:10.1016/s0140-6736(25)02165-8

Journal article 378 views 373 downloads

Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial

Deborah B Horn, Donna H Ryan, Sanja Giljanovic Kis, Breno Alves, Yiming Mu, Sin Gon Kim, Jens Aberle, Steve Bain

, Sheryl Allen, Elizabeth Sarker, Qiwei Wu, Adam Stefanski, Irina Jouravskaya

The Lancet

Swansea University Author: Steve Bain

PDF | Accepted Manuscript

Author accepted manuscript document released under the terms of a Creative Commons CC-BY licence using the Swansea University Research Publications Policy (rights retention).
Download (232.99KB)

Check full text

DOI (Published version): 10.1016/s0140-6736(25)02165-8

Published in:	The Lancet
ISSN:	0140-6736 1474-547X
Published:	Elsevier BV 2025
Online Access:	Check full text
URI:	https://cronfa.swan.ac.uk/Record/cronfa71022

first_indexed	2025-11-28T13:41:45Z
last_indexed	2025-12-09T14:20:05Z
id	cronfa71022
recordtype	SURis
fullrecord	<?xml version="1.0"?><rfc1807><datestamp>2025-12-08T11:41:33.8373617</datestamp><bib-version>v2</bib-version><id>71022</id><entry>2025-11-28</entry><title>Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2025-11-28</date><deptcode>MEDS</deptcode><abstract/><type>Journal Article</type><journal>The Lancet</journal><volume>0</volume><journalNumber/><paginationStart/><paginationEnd/><publisher>Elsevier BV</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>0140-6736</issnPrint><issnElectronic>1474-547X</issnElectronic><keywords/><publishedDay>20</publishedDay><publishedMonth>11</publishedMonth><publishedYear>2025</publishedYear><publishedDate>2025-11-20</publishedDate><doi>10.1016/s0140-6736(25)02165-8</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm>Not Required</apcterm><funders>This study was funded by Eli Lilly and Company.</funders><projectreference/><lastEdited>2025-12-08T11:41:33.8373617</lastEdited><Created>2025-11-28T13:40:28.3195636</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Biomedical Science</level></path><authors><author><firstname>Deborah B</firstname><surname>Horn</surname><order>1</order></author><author><firstname>Donna H</firstname><surname>Ryan</surname><order>2</order></author><author><firstname>Sanja Giljanovic</firstname><surname>Kis</surname><order>3</order></author><author><firstname>Breno</firstname><surname>Alves</surname><order>4</order></author><author><firstname>Yiming</firstname><surname>Mu</surname><order>5</order></author><author><firstname>Sin Gon</firstname><surname>Kim</surname><order>6</order></author><author><firstname>Jens</firstname><surname>Aberle</surname><order>7</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>8</order></author><author><firstname>Sheryl</firstname><surname>Allen</surname><order>9</order></author><author><firstname>Elizabeth</firstname><surname>Sarker</surname><order>10</order></author><author><firstname>Qiwei</firstname><surname>Wu</surname><order>11</order></author><author><firstname>Adam</firstname><surname>Stefanski</surname><order>12</order></author><author><firstname>Irina</firstname><surname>Jouravskaya</surname><order>13</order></author></authors><documents><document><filename>71022__35706__6985a2612d384e3382cae4d0841551d4.pdf</filename><originalFilename>Horn2025.pdf</originalFilename><uploaded>2025-11-28T13:41:12.6961182</uploaded><type>Output</type><contentLength>238583</contentLength><contentType>application/pdf</contentType><version>Accepted Manuscript</version><cronfaStatus>true</cronfaStatus><documentNotes>Author accepted manuscript document released under the terms of a Creative Commons CC-BY licence using the Swansea University Research Publications Policy (rights retention).</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>https://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling	2025-12-08T11:41:33.8373617 v2 71022 2025-11-28 Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 2025-11-28 MEDS Journal Article The Lancet 0 Elsevier BV 0140-6736 1474-547X 20 11 2025 2025-11-20 10.1016/s0140-6736(25)02165-8 COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University Not Required This study was funded by Eli Lilly and Company. 2025-12-08T11:41:33.8373617 2025-11-28T13:40:28.3195636 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Biomedical Science Deborah B Horn 1 Donna H Ryan 2 Sanja Giljanovic Kis 3 Breno Alves 4 Yiming Mu 5 Sin Gon Kim 6 Jens Aberle 7 Steve Bain 0000-0001-8519-4964 8 Sheryl Allen 9 Elizabeth Sarker 10 Qiwei Wu 11 Adam Stefanski 12 Irina Jouravskaya 13 71022__35706__6985a2612d384e3382cae4d0841551d4.pdf Horn2025.pdf 2025-11-28T13:41:12.6961182 Output 238583 application/pdf Accepted Manuscript true Author accepted manuscript document released under the terms of a Creative Commons CC-BY licence using the Swansea University Research Publications Policy (rights retention). true eng https://creativecommons.org/licenses/by/4.0/
title	Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
spellingShingle	Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial Steve Bain
title_short	Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
title_full	Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
title_fullStr	Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
title_full_unstemmed	Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
title_sort	Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
author_id_str_mv	5399f4c6e6a70f3608a084ddb938511a
author_id_fullname_str_mv	5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain
author	Steve Bain
author2	Deborah B Horn Donna H Ryan Sanja Giljanovic Kis Breno Alves Yiming Mu Sin Gon Kim Jens Aberle Steve Bain Sheryl Allen Elizabeth Sarker Qiwei Wu Adam Stefanski Irina Jouravskaya
format	Journal article
container_title	The Lancet
container_volume	0
publishDate	2025
institution	Swansea University
issn	0140-6736 1474-547X
doi_str_mv	10.1016/s0140-6736(25)02165-8
publisher	Elsevier BV
college_str	Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id	facultyofmedicinehealthandlifesciences
hierarchy_top_title	Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id	facultyofmedicinehealthandlifesciences
hierarchy_parent_title	Faculty of Medicine, Health and Life Sciences
department_str	Swansea University Medical School - Biomedical Science{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Biomedical Science
document_store_str	1
active_str	0
published_date	2025-11-20T05:33:00Z
_version_	1856805777364221952
score	11.095924

Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial

Similar Items